Verition Fund Management LLC Buys New Stake in DENTSPLY SIRONA Inc (XRAY)

Verition Fund Management LLC bought a new position in shares of DENTSPLY SIRONA Inc (NASDAQ:XRAY) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 59,744 shares of the medical instruments supplier’s stock, valued at approximately $3,006,000.

A number of other large investors also recently added to or reduced their stakes in XRAY. NuWave Investment Management LLC purchased a new stake in DENTSPLY SIRONA during the 4th quarter worth approximately $121,000. Focused Wealth Management Inc grew its position in DENTSPLY SIRONA by 79.2% during the 4th quarter. Focused Wealth Management Inc now owns 2,600 shares of the medical instruments supplier’s stock worth $171,000 after purchasing an additional 1,149 shares during the last quarter. Capital One National Association purchased a new stake in DENTSPLY SIRONA during the 4th quarter worth approximately $204,000. Boston Common Asset Management LLC purchased a new stake in DENTSPLY SIRONA during the 4th quarter worth approximately $212,000. Finally, Highland Capital Management LP purchased a new stake in DENTSPLY SIRONA during the 4th quarter worth approximately $230,000. 93.85% of the stock is currently owned by institutional investors.

XRAY stock opened at $44.37 on Thursday. The firm has a market capitalization of $9.87 billion, a PE ratio of 16.69, a price-to-earnings-growth ratio of 2.24 and a beta of 1.23. The company has a current ratio of 2.23, a quick ratio of 1.46 and a debt-to-equity ratio of 0.25. DENTSPLY SIRONA Inc has a 12 month low of $41.64 and a 12 month high of $68.98.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its quarterly earnings data on Sunday, May 6th. The medical instruments supplier reported $0.45 EPS for the quarter, beating the consensus estimate of $0.42 by $0.03. The business had revenue of $956.10 million for the quarter, compared to the consensus estimate of $942.20 million. DENTSPLY SIRONA had a negative net margin of 38.32% and a positive return on equity of 8.63%. The business’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same period in the prior year, the firm earned $0.49 EPS. research analysts expect that DENTSPLY SIRONA Inc will post 2.58 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, July 13th. Investors of record on Friday, June 29th will be paid a $0.0875 dividend. This represents a $0.35 annualized dividend and a dividend yield of 0.79%. The ex-dividend date is Thursday, June 28th. DENTSPLY SIRONA’s dividend payout ratio is currently 13.16%.

In related news, Director Michael C. Alfano sold 1,404 shares of the business’s stock in a transaction on Wednesday, May 30th. The shares were sold at an average price of $45.83, for a total value of $64,345.32. Following the completion of the transaction, the director now directly owns 13,458 shares in the company, valued at approximately $616,780.14. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Donald M. Jr. Casey bought 22,500 shares of the firm’s stock in a transaction that occurred on Wednesday, May 9th. The stock was purchased at an average price of $44.52 per share, with a total value of $1,001,700.00. Following the completion of the purchase, the chief executive officer now owns 92,408 shares in the company, valued at $4,114,004.16. The disclosure for this purchase can be found here. Over the last quarter, insiders sold 7,856 shares of company stock valued at $349,153. Company insiders own 1.93% of the company’s stock.

Several research firms have weighed in on XRAY. Zacks Investment Research raised shares of DENTSPLY SIRONA from a “strong sell” rating to a “hold” rating in a research report on Wednesday, June 6th. Barclays reissued a “hold” rating and set a $55.00 target price on shares of DENTSPLY SIRONA in a research report on Tuesday, May 8th. ValuEngine downgraded shares of DENTSPLY SIRONA from a “hold” rating to a “sell” rating in a research report on Wednesday, May 2nd. Robert W. Baird dropped their target price on shares of DENTSPLY SIRONA to $71.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 8th. Finally, BidaskClub raised shares of DENTSPLY SIRONA from a “strong sell” rating to a “sell” rating in a report on Wednesday. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and nine have issued a buy rating to the stock. DENTSPLY SIRONA currently has an average rating of “Hold” and a consensus target price of $63.38.

DENTSPLY SIRONA Company Profile

DENTSPLY SIRONA Inc designs, develops, manufactures, and markets various dental and oral health products, and other consumable healthcare products primarily for the professional dental market worldwide. The company operates in two segments, Technologies & Equipment; and Consumables. Its dental supplies include endodontic instruments and materials, dental anesthetics, prophylaxis pastes, dental sealants, impression materials, restorative materials, tooth whiteners, and topical fluoride products; and small equipment products comprise dental hand pieces, intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers.

Want to see what other hedge funds are holding XRAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DENTSPLY SIRONA Inc (NASDAQ:XRAY).

Institutional Ownership by Quarter for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit